Balkan endemic nephropathy (BEN) is a unique, chronic renal disease frequently associated with upper urothelial cancer (UUC). It only affects residents of specific farming villages located along tributaries of the Danube River in Bosnia-Herzegovina, Croatia, Macedonia, Serbia, Bulgaria, and Romania where it is estimated that ~100,000 individuals are at risk of BEN, while ~25,000 have the disease. This review summarises current findings on the aetiology of BEN. Over the last 50 years, several hypotheses on the cause of BEN have been formulated, including mycotoxins, heavy metals, viruses, and trace-element insufficiencies. However, recent molecular epidemiological studies provide a strong case that chronic dietary exposure to aristolochic acid (AA) a principal component of Aristolochia clematitis which grows as a weed in the wheat fields of the endemic regions is the cause of BEN and associated UUC. One of the still enigmatic features of BEN that need to be resolved is why the prevalence of BEN is only 3-7 %. This suggests that individual genetic susceptibilities to AA exist in humans. In fact dietary ingestion of AA along with individual genetic susceptibility provides a scenario that plausibly can explain all the peculiarities of BEN such as geographical distribution and high risk of urothelial cancer. For the countries harbouring BEN implementing public health measures to avoid AA exposure is of the utmost importance because this seems to be the best way to eradicate this once mysterious disease to which the residents of BEN villages have been completely and utterly at mercy for so long.

Analytical and Environmental Sciences Division MRC PHE Centre for Environmental and Health King's College London 150 Stamford Street London SE1 9NH UK

Department of Biochemistry Faculty of Science Charles University Albertov 2030 128 40 Prague 2 Czech Republic

Division of Radiopharmaceutical Chemistry Im Neuenheimer Feld 280 69120 Heidelberg Germany

NIHR Health Protection Research Unit in Health Impact of Environmental Hazards at King's College London in partnership with Public Health England Franklin Wilkins Building 150 Stamford Street London SE1 9NH UK

Zobrazit více v PubMed

Alecković M, Mesić E, Trnacević S, Stipancić Z, Hamidović D, Hasanović E. Glomerular filtration rate in examined population of Bosnian Posavina—region of Balkan Endemic Nephropathy. Bosn J Basic Med Sci. 2010;10:S68–S72. PubMed PMC

Anandagoda N, Lord GM. Preventing aristolochic acid nephropathy. Clin J Am Soc Nephrol. 2015;10:167–168. doi: 10.2215/CJN.12391214. PubMed DOI PMC

Andonova IE, Sarueva RB, Horvath AD, Simeonov VA, Dimitrov PS, Petropoulos EA, Ganev VS. Balkan endemic nephropathy and genetic variants of glutathione S-transferases. J Nephrol. 2004;17:390–398. PubMed

Arlt VM, Pfohl-Leszkowicz A, Cosyns J, Schmeiser HH. Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patients with Chinese herbs nephropathy. Mutat Res. 2001;494:143–150. doi: 10.1016/S1383-5718(01)00188-7. PubMed DOI

Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis. 2002;17:265–277. doi: 10.1093/mutage/17.4.265. PubMed DOI

Arlt VM, Ferluga D, Stiborova M, Pfohl-Leszkowicz A, Vukelic M, Ceovic S, Schmeiser HH, Cosyns JP. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer. 2002;101:500–502. doi: 10.1002/ijc.10602. PubMed DOI

Arlt VM, Alunni-Perret V, Quatrehomme G, Ohayon P, Albano L, Gaïd H, Michiels JF, Meyrier A, Cassuto E, Wiessler M, Schmeiser HH, Cosyns JP. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int J Cancer. 2004;111:977–980. doi: 10.1002/ijc.20316. PubMed DOI

Arlt VM, Stiborova M, vom Brocke J, Simoes ML, Lord GM, Nortier JL, Hollstein M, Phillips DH, Schmeiser HH. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis. 2007;28:2253–2261. doi: 10.1093/carcin/bgm082. PubMed DOI

Arlt VM, Levova K, Barta F, Shi Z, Evans JD, Frei E, Schmeiser HH, Nebert DW, Phillips DH, Stiborova M. Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice. Chem Res Toxicol. 2011;24:1710–1719. doi: 10.1021/tx200259y. PubMed DOI

Arlt VM, Zuo J, Trenz K, Roufosse CA, Lord GM, Nortier JL, Schmeiser HH, Hollstein M, Phillips DH. Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int J Cancer. 2011;128:21–32. doi: 10.1002/ijc.25324. PubMed DOI

Arlt VM, Meinl W, Florian S, Nagy E, Barta, Thomann M, Mrizova I, Krais AM, Liu M, Richards M, Mirza A, Kopka K, Phillips DH, Glatt H-R, Stiborova M, Schmeiser HH (2016) Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone. Arch Toxicol (in press) PubMed PMC

Arsenović A, Bukvić D, Trbojević S, Marić I, Djukanović L. Detection of renal dysfunctions in family members of patients with Balkan endemic nephropathy. Am J Nephrol. 2005;25:50–54. doi: 10.1159/000084105. PubMed DOI

Atanasova SY, von Ahsen N, Toncheva DI, Dimitrov TG, Oellerich M, Amstrong VM. Genetic polymorphism of cytochrome P450 among patients with Balkan endemic nephropathy (BEN) Clin Biochem. 2005;38:223–228. doi: 10.1016/j.clinbiochem.2004.12.002. PubMed DOI

Aydin S, Dekairelle AF, Ambroise J, Durant JF, Heusterspreute M, Guiot Y, Cosyns JP, Gala JL. Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium using laser capture microdissection. PLoS One. 2014;9:e106301. doi: 10.1371/journal.pone.0106301. PubMed DOI PMC

Bamias G, Boletis J. Balkan nephropathy: evolution of our knowledge. Am J Kidney Dis. 2008;52:606–616. doi: 10.1053/j.ajkd.2008.05.024. PubMed DOI PMC

Barta F, Levova K, Hodek P, Schmeiser HH, Arlt VM, Stiborova M. The effects of heavy metal ions, phthalates and ochratoxin A on oxidation of carcinogenic aristolochic acid I causing Balkan endemic nephropathy. Neuro Endocrinol Lett. 2015;36(suppl 1):13–21. PubMed

Bárta F, Levová K, Frei E, Schmeiser HH, Arlt VM, Stiborová M. The effect of aristolochic acid I on NAD(P)H:quinone oxidoreductase expression in mice and rats—a comparative study. Mutat Res. 2014;768:1–7. doi: 10.1016/j.mrgentox.2014.01.012. PubMed DOI

Basic-Jukic N, Hrsak-Puljic I, Kes P, Bubic-Filipi L, Pasini J, Hudolin T, Kastelan Z, Reiner Z, Kordic M, Brunetta B, Juric I. Renal transplantation in patients with Balkan endemic nephropathy. Transplant Proc. 2007;39:1432–1435. doi: 10.1016/j.transproceed.2006.11.019. PubMed DOI

Batuman V. Fifty years of Balkan endemic nephropathy: daunting questions, elusive answers. Kidney Int. 2006;69:644–646. doi: 10.1038/sj.ki.5000231. PubMed DOI

Bendadani C, Meinl W, Monien B, Dobbernack G, Florian S, Engst W, Nolden T, Himmelbauer H, Glatt H. Determination of sulfotransferase forms involved in the metabolic activation of the genotoxicant 1-hydroxymethylpyrene using bacterially expressed enzymes and genetically modified mouse models. Chem Res Toxicol. 2014;27:1060–1069. doi: 10.1021/tx500129g. PubMed DOI

Bieler CA, Stiborova M, Wiessler M, Cosyns JP, van Ypersele de Strihou C, Schmeiser HH. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis. 1997;18:1063–1067. doi: 10.1093/carcin/18.5.1063. PubMed DOI

Broschard TH, Wiessler M, von der Lieth CW, Schmeiser HH. Translesional synthesis on DNA templates containing site-specifically placed deoxyadenosine and deoxyguanosine adducts formed by the plant carcinogen aristolochic acid. Carcinogenesis. 1994;15:2331–2340. doi: 10.1093/carcin/15.10.2331. PubMed DOI

Bui-Klimke T, Wu F. Evaluating weight of evidence in the mystery of Balkan endemic nephropathy. Risk Anal. 2014;34:1688–1705. doi: 10.1111/risa.12239. PubMed DOI PMC

Bunnell JE, Tatu CA, Lerch HE, Olea RA, Suitt SE, Kolker A. Evaluating nephrotoxicity of high-molecular-weight organic compounds in drinking water from lignite aquifers. J Toxicol Environ Health A. 2007;70:2089–2091. doi: 10.1080/15287390701551274. PubMed DOI

Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmoller J, Zanger UM, Wojnowski L. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR) J Biol Chem. 2004;279:38379–38385. doi: 10.1074/jbc.M404949200. PubMed DOI

Castegnaro M, Canadas D, Vrabcheva T, Petkova-Bocharova T, Chernozemsky IN, Pfohl-Leszkowicz A. Balkan endemic nephropathy: role of ochratoxins A through biomarkers. Mol Nutr Food Res. 2006;50:519–529. doi: 10.1002/mnfr.200500182. PubMed DOI

Chan W, Cu L, Xu G, Cai Z. Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006;20:1755–1760. doi: 10.1002/rcm.2513. PubMed DOI

Chan W, Luo HB, Zheng Y, Cheng YK, Cai Z. Investigation of the metabolism and reductive activation of carcinogenic aristolochic acid in rats. Drug Metab Dispos. 2007;35:866–874. doi: 10.1124/dmd.106.013979. PubMed DOI

Chen M, Gong L, Qi X, Xing G, Luan Y, Wu Y, Xiao Y, Yao J, Li Y, Xue X, Pan G, Ren J. Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. Toxicol Sci. 2011;122:288–296. doi: 10.1093/toxsci/kfr138. PubMed DOI

Chen B, Bai Y, Sun M, Ni X, Yang Y, Yang Y, Zheng S, Xu F, Dai S. Glutathione S-transferases T1 null genotype is associated with susceptibility to aristolochic acid nephropathy. Int Urol Nephrol. 2012;44:301–307. doi: 10.1007/s11255-011-0082-z. PubMed DOI

Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA. 2012;109:8241–8246. doi: 10.1073/pnas.1119920109. PubMed DOI PMC

Chen CH, Dickman KG, Huang CY, Shun CT, Tai HC, Huang KH, Wang SM, Lee YJ, Grollman AP, Pu YS. Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma. Oncotarget. 2016;29:45225–45236. PubMed PMC

Cosyns JP. Aristolochic acid and “Chinese herbs nephropathy”: a review of the evidence to date. Drug Saf. 2003;26:33–48. doi: 10.2165/00002018-200326010-00004. PubMed DOI

Cosyns JP, Jadoul M, Squifflet JP, De Plaen JF, Ferluga D, van Ypersele de Strihou C. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int. 1994;45:1680–1688. doi: 10.1038/ki.1994.220. PubMed DOI

Cosyns JP, Goebbels RM, Liberton V, Schmeiser HH, Bieler CA, Bernard AM. Chinese herbs nephropathy-associated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats. Arch Toxicol. 1998;72:738–743. doi: 10.1007/s002040050568. PubMed DOI

Cosyns JP, Jadoul M, Squifflet JP, Wese FX, van Ypersele de Strihou C. Urothelial lesions in Chinese herb nephropathy. Am J Kidney Dis. 1999;33:1011–1017. doi: 10.1016/S0272-6386(99)70136-8. PubMed DOI

Cukuranovic R, Jovanovic I, Miljkovic S, Stefanovic N, Vlajkovic S, Prokopovic M, Stefanovic V. Hemodialysis treatment in patients with Balkan endemic nephropathy: an epidemiological study. Ren Fail. 2007;29:805–810. doi: 10.1080/08860220701573475. PubMed DOI

Danilovic V, Djurisic M, Mokranjac M, Stojimirovic B, Zivojinovic J, Stojakovic P. Chronic nephritis due to lead poisoning by digestive route (flour) [Néphrites chroniques provoquées par l’intoxication au plomb par voie digestive (farine), in French] Presse Méd. 1957;65:2039–2040. PubMed

De Broe ME. Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. Kidney Int. 2012;81:513–515. doi: 10.1038/ki.2011.428. PubMed DOI

Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74:158–169. doi: 10.1038/ki.2008.129. PubMed DOI

Dika Ž, Antoine MH, Husson C, De Prez EG, Kos J, Mišić M, Fuček M, Čvorišćec D, Bourgeade MF, Nortier JL, Jelaković B. Evaluation of diagnostic criteria for endemic nephropathy. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2014;35:47–50. PubMed

Dimitrov P, Tsolova S, Georgieva R, Bozhilova D, Simeonov V, Bonev A, Karmaus W. Clinical markers in adult offspring of families with and without Balkan endemic nephropathy. Kidney Int. 2006;69:723–729. doi: 10.1038/sj.ki.5000120. PubMed DOI

Djukanović L, Marić I, Marinković J, Ignjatović S, Bukvić D. Evaluation of criteria for the diagnosis of Balkan endemic nephropathy. Ren Fail. 2007;29:607–614. doi: 10.1080/08860220701392231. PubMed DOI

Dong H, Suzuki N, Torres MC, Bonala RR, Johnson F, Grollman AP, Shibutani S. Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab Dispos. 2006;34:1122–1127. doi: 10.1124/dmd.105.008706. PubMed DOI

Dračínská H, Bárta F, Levová K, Hudecová A, Moserová M, Schmeiser HH, Kopka K, Frei E, Arlt VM, Stiborová M. Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo. Toxicology. 2016;344:7–8. doi: 10.1016/j.tox.2016.01.011. PubMed DOI PMC

Drahushuk AT, McGarrigle BP, Larsen KE, Stegeman JJ, Olson JR. Detection of CYP1A1 protein in human liver and induction by TCDD in precision-cut liver slices incubated in dynamic organ culture. Carcinogenesis. 1998;19:1361–1368. doi: 10.1093/carcin/19.8.1361. PubMed DOI

European Food Safety Authority (EFSA) European Food Safety Authority. Opinion of the Scientific Panel on contaminants in the Food Chain of the EFSA on a request from the Commission related to ochratoxin A in food. EFSA J. 2006;365:1–56. PubMed

Feder GL, Radovanovic Z, Finkelman RB. Relationship between weathered coal deposits and the etiology of Balkan endemic nephropathy. Kidney Int Suppl. 1991;34:S9–S11. PubMed

Feldmeyer N, Schmeiser HH, Muehlbauer KR, Belharazem D, Knyazev Y, Nedelko T, Hollstein M. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat Res. 2006;608:163–168. doi: 10.1016/j.mrgentox.2006.02.017. PubMed DOI

Gautier J, Richoz J, Welti DH, Markovic J, Gremaud E, Guengerich FP, Turesky RJ. Metabolism of ochratoxin A: absence of formation of genotoxic derivatives by human and rat enzymes. Chem Res Toxicol. 2001;14:34–45. doi: 10.1021/tx000070j. PubMed DOI

Godin M, Fillastre JP, Simon P, Francois A, Roy FL, Morin JP. Is ochratoxin a nephrotoxic in human beings? Adv Nephrol Necker Hosp. 1997;26:181–206. PubMed

Gökmen MR, Cosyns JP, Arlt VM, Stiborová M, Phillips DH, Schmeiser HH, Simmonds MSJ, Look HT, Vanherweghem JL, Nortier JL, Lord GM. The epidemiology, diagnosis and management of Aristolochic Acid Nephropathy: a narrative review. Ann Intern Med. 2013;158:469–477. doi: 10.7326/0003-4819-158-6-201303190-00006. PubMed DOI

Grollman AP. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen. 2013;54:1–7. doi: 10.1002/em.21756. PubMed DOI

Grollman AP, Jelakovic B. Role of environmental toxins in endemic (Balkan) nephropathy. October 2006, Zagreb, Croatia. J Am Soc Nephrol. 2007;18:2817–2823. doi: 10.1681/ASN.2007050537. PubMed DOI

Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelic M, Jelakovic B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA. 2007;104:12129–12134. doi: 10.1073/pnas.0701248104. PubMed DOI PMC

Gross-Steinmeyer K, Weymann J, Hege HG, Metzler M. Metabolism and lack of DNA reactivity of the mycotoxin ochratoxin a in cultured rat and human primary hepatocytes. J Agric Food Chem. 2002;50:938–945. doi: 10.1021/jf0111817. PubMed DOI

Hald B. Porcine nephropathy in Europe. IARC Sci Publ. 1991;115:49–56. PubMed

Hashimoto K, Zaitseva IN, Bonala R, Attaluri S, Ozga K, Iden CR, Johnson F, Moriya M, Grollman AP, Sidorenko VS. Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I and N-hydroxyaristolactam I in human cells. Carcinogenesis. 2016;37:647–655. doi: 10.1093/carcin/bgw045. PubMed DOI PMC

He P, Court RH, Greenblatt DJ, Von Moltke LL. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther. 2005;77:373–387. doi: 10.1016/j.clpt.2004.11.112. PubMed DOI

Heinrich M, Chan J, Wanke S, Neinhuis C, Simmonds MS. Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2—a global assessment based on bibliographic sources. J Ethnopharmacol. 2009;125:108–144. doi: 10.1016/j.jep.2009.05.028. PubMed DOI

Hoang ML, Chen CH, Sidorenko VS, He J, Dickman KG, Yun BH, Moriya M, Niknafs N, Douville C, Karchin R, Turesky RJ, Pu YS, Vogelstein B, Papadopoulos N, Grollman AP, Kinzler KW, Rosenquist TA (2013) Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med 197ra102 PubMed PMC

IARC (2012) IARC Monogr. Eval. Carcinog. Risk Hum. 100A

Ivić M. The problem of etiology of endemic nephropathy. Liječ Vjesn. 1969;91:1273–1281. PubMed

Ivić M, Lovriæ B. Carcinogenic action of Aristolochia [in Serbian] Acta Medica Med. 1967;5:1–3.

Jaiswal AK. Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic Biol Med. 2000;29:254–262. doi: 10.1016/S0891-5849(00)00306-3. PubMed DOI

Jankovic VL, Hattori T, Dolicanin Z, Visnjic M, Krstic M, Ilic I, Cukuranovic R, Rajic M, Stefanovic V. Upper urothelial carcinoma in Balkan endemic nephropathy and non-endemic regions: a comparative study of pathological features. Pathol Res Pract. 2009;205:89–96. doi: 10.1016/j.prp.2008.09.002. PubMed DOI

Jelakovic B, Nikolic J, Radovanovic Z, Nortier J, Cosyns JP, Grollman AP, Basic-Jukic N, Belicza M, Bukvic D, Cavaljuga S, Cvoriscec D, Cvitkovic A, Dika Z, Dimitrov P, Dukanovic L, Edwards K, Ferluga D, Fustar-Preradovic L, Gluhovschi G, Imamovic G, Jakovina T, Kes P, Leko N, Medverec Z, Mesic E, Miletic-Medved M, Miller F, Pavlovic N, Pasini J, Plestina S, Polenakovic M, Stefanovic V, Tomic K, Trnacevic S, Vukovic Lela I, Stern-Padovan R. Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy. Nephrol Dial Transplant. 2014;29:2020–2027. doi: 10.1093/ndt/gft384. PubMed DOI PMC

Jelaković B, Karanović S, Vuković-Lela I, Miller F, Edwards KL, Nikolić J, Tomić K, Slade N, Brdar B, Turesky RJ, Stipančić Ž, Dittrich D, Grollman AP, Dickman KG. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int. 2012;81:559–567. doi: 10.1038/ki.2011.371. PubMed DOI PMC

Jerabek P, Martinek V, Stiborova M. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1. Neuro Endocrinol Lett. 2012;33(Suppl 3):25–32. PubMed

Karmaus W, Dimitrov P, Simeonov V, Tsolova S, Bonev A, Georgieva R. Metals and kidney and controls: a two-year follow-up study. Environ Health. 2008;7:11. doi: 10.1186/1476-069X-7-11. PubMed DOI PMC

Kazantzis G (1967) Comment in the general discussion: possible nephrotoxic agents. In: Wolstenholme GE, Knight J (eds) The Balkan nephropathy. CIBA Foundation, Boston, p 114

KDIGO 2012 (2013) Clinical practice guideline for the evaluation and management of chronic kidney disease. Chapter 1: definition and classification of CKD. Kidney Int Suppl 3:19–62 PubMed PMC

Kocic G, Cukuranovic J, Stoimenov TJ, Cukuranovic R, Djordjevic V, Bogdanovic D, Stefanovic V. Global and specific histone acetylation pattern in patients with Balkan endemic nephropathy, a worldwide disease. Ren Fail. 2014;36:1078–1082. doi: 10.3109/0886022X.2014.917562. PubMed DOI

Krogh P, Hald B, Plestina R, Ceović S. Balkan (endemic) nephropathy and foodborn ochratoxin A: preliminary results of a survey of foodstuffs. Acta Pathol Microbiol Scand B. 1977;85:238–240. PubMed

Krumbiegel G, Hallensleben J, Mennicke WH, Rittmann N. Studies on the metabolism of aristolochic acids I and II. Xenobiotica. 1987;17:981–991. doi: 10.3109/00498258709044197. PubMed DOI

Kucab JE, Phillips DH, Arlt VM. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model. FEBS J. 2010;277:2567–2583. doi: 10.1111/j.1742-4658.2010.07676.x. PubMed DOI

Levova K, Moserova M, Nebert DW, Phillips DH, Frei E, Schmeiser HH, Arlt VM, Stiborová M. NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I. Toxicol Appl Pharmacol. 2012;265:360–367. doi: 10.1016/j.taap.2012.09.004. PubMed DOI

Levová K, Moserová M, Kotrbová V, Šulc M, Henderson CJ, Wolf CR, Phillips DH, Frei E, Schmeiser HH, Mareš J, Arlt VM, Stiborová M. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. Toxicol Sci. 2011;121:43–56. doi: 10.1093/toxsci/kfr050. PubMed DOI

Li Y, Jaiswal AK. Human antioxidant-response-element-mediated regulation of type 1 NAD(P)H:quinone oxidoreductase gene expression. Effect of sulfhydryl modifying agents. Eur J Biochem. 1994;226:31–39. doi: 10.1111/j.1432-1033.1994.tb20023.x. PubMed DOI

Li J, Zhang L, Jiang Z, Shu B, Li F, Bao Q, Zhang L. Toxicities of aristolochic acid I and aristololactam I in cultured renal epithelial cells. Toxicol In Vitro. 2010;24:1092–1097. doi: 10.1016/j.tiv.2010.03.012. PubMed DOI

Liu Z, Hergenhahn M, Schmeiser HH, Wogan GN, Hong A, Hollstein M. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci USA. 2004;101:2963–2968. doi: 10.1073/pnas.0308607101. PubMed DOI PMC

Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD. Urothelial malignant disease and Chinese herbal nephropathy. Lancet. 2001;358:1515–1516. doi: 10.1016/S0140-6736(01)06576-X. PubMed DOI

Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, Schmeiser HH. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis. 2004;43:e11–e17. doi: 10.1053/j.ajkd.2003.11.024. PubMed DOI

Maaroufi K, Achour A, Betbeder AM, Hammami M, Ellouz F, Creppy EE, Bacha H. Foodstuffs and human blood contamination by the mycotoxin ochratoxin A: correlation with chronic interstitial nephropathy in Tunisia. Arch Toxicol. 1995;69:552–558. doi: 10.1007/s002040050211. PubMed DOI

Maharaj SV. Limitations and plausibility of the Pliocene lignite hypothesis in explaining the etiology of Balkan endemic nephropathy. Int J Occup Environ Health. 2014;20:77–91. doi: 10.1179/2049396713Y.0000000046. PubMed DOI PMC

Maharaj SV, Orem WH, Tatu CA, Lerch HE, 3rd, Szilagyi DN. Organic compounds in water extracts of coal: links to Balkan endemic nephropathy. Environ Geochem Health. 2014;36:1–17. doi: 10.1007/s10653-013-9515-1. PubMed DOI PMC

Maier P, Schawalder H, Weibel B. Low oxygen tension as found in tissues in vivo, alters the mutagenic activity of aristolochic acid I and II. Environ Mol Mutagen. 1987;10:275–284. doi: 10.1002/em.2850100306. PubMed DOI

Maksimovic ZJ. Selenium deficiency and Balkan endemic nephropathy. Kidney Int Suppl. 1991;34:S12–S14. PubMed

Maksimović ZJ, Djujić I. Selenium deficiency in Serbia and possible effects on health. Biomed Environ Sci. 1997;10:300–306. PubMed

Maksimovic ZJ, Djujic I, Jovic V, Rsumovic M. Selenium deficiency in Yugoslavia. Biol Trace Element Res. 1992;33:187–196. doi: 10.1007/BF02784022. PubMed DOI

Mally A, Dekant W. DNA adduct formation by ochratoxin A: review of the available evidence. Food Addit Contam. 2005;22(suppl 1):65–74. doi: 10.1080/02652030500317544. PubMed DOI

Mally A, Dekant W. Mycotoxins and the kidney: modes of action for renal tumor formation by ochratoxin A in rodents. Mol Nutr Food Res. 2009;53:467–478. doi: 10.1002/mnfr.200800149. PubMed DOI

Mally A, Zepnik H, Wanek P, Eder E, Dingley K, Ihmels H, Völkel W, Dekant W. Ochratoxin A: lack of formation of covalent DNA adducts. Chem Res Toxicol. 2004;17:234–242. doi: 10.1021/tx034188m. PubMed DOI

Manderville RA. A case for the genotoxicity of ochratoxin A by bioactivation and covalent DNA adduction. Chem Res Toxicol. 2005;18:1091–1097. doi: 10.1021/tx050070p. PubMed DOI

Mantle PG, Faucet-Marquis V, Manderville RA, Squillaci B, Pfohl-Leszkowicz A. Structures of covalent adducts between DNA and ochratoxin a: a new factor in debate about genotoxicity and human risk assessment. Chem Res Toxicol. 2010;23:89–98. doi: 10.1021/tx900295a. PubMed DOI

Markovic B, Lebedev S, Djordjevic M, Arambasic M. Endemic urinary tract cancer in Bulgaria, Yugoslavia, and Romania: etiology and pathogenesis. Med Biol Environ. 1976;4:1–2.

Martinek V, Kubickova B, Arlt VM, Frei E, Schmeiser HH, Hudecek J, Stiborova M. Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases. Neuro Endocrinol Lett. 2011;32(Suppl 1):57–70. PubMed

Martinez MC, Nortier J, Vereerstaeten P, Vanherweghem JL. Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose. Nephrol Dial Transplant. 2002;17:408–412. doi: 10.1093/ndt/17.3.408. PubMed DOI

Meinl W, Pabel U, Osterloh-Quiroz M, Hengstler JG, Glatt H. Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int J Cancer. 2006;118:1090–1097. doi: 10.1002/ijc.21480. PubMed DOI

Miletić-Medved M, Domijan AM, Peraica M. Recent data on endemic nephropathy and related urothelial tumors in Croatia. Wien Klin Wochenschr. 2005;117:604–609. doi: 10.1007/s00508-005-0426-8. PubMed DOI

Milichovský J, Bárta F, Schmeiser HH, Arlt VM, Frei E, Stiborová M, Martínek V (2016) Active site mutations as a suitable tool contributing to explain a mechanism of aristolochic acid I nitroreduction by cytochromes P450 1A1, 1A2, and 1B1. Int J Mol Sci 7:pii: E213 PubMed PMC

Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelakovic B, Wu L, Truong S, Fernandes A, Grollman AP. TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer. 2011;129:1532–1536. doi: 10.1002/ijc.26077. PubMed DOI

National Toxicology Program (2009) Aristolochic acids 12th report on carcinogens. National Toxicology Program, Public Health Service, US Department of Health and Human Services, Research Triangle Park, NC, pp 45–49

Nebert DW, Jones JE. Regulation of the mammalian cytochrome P1-450 (CYP1A1) gene. Int J Biochem. 1989;21:243–252. doi: 10.1016/0020-711X(89)90182-1. PubMed DOI

Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, Dalton TP. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol. 2000;59:65–85. doi: 10.1016/S0006-2952(99)00310-X. PubMed DOI

Nedelko T, Arlt VM, Phillips DH, Hollstein M. TP53 mutation signature supports involvement of aristolochic acid in the etiology of endemic nephropathy-associated tumours. Int J Cancer. 2009;124:987–990. doi: 10.1002/ijc.24006. PubMed DOI

Nichifor E, Balea M, Rusu G, Melencu M, Ghiordanescu N, Cristescu I, Dovlete C, Sonoc S. Studies on the familial character of endemic Balkan nephropathy. Possible role of the toxic hydric factor in the determination of “familial agglomerations” in endemic Balkan nephropathy. Med Intern. 1985;23:229–237. PubMed

Nikolov IG, Chernozemsky IN, Idle JR. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor. IARC Sci Publ. 1991;115:289–296. PubMed

Nik-Zainal S, Kucab JE, Morganella S, Glodzik D, Alexandrov LB, Arlt VM, Weninger A, Hollstein M, Stratton MR, Phillips DH. The genome as a record of environmental exposure. Mutagenesis. 2015;30:763–770. PubMed PMC

Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) N Engl J Med. 2000;342:1686–1692. doi: 10.1056/NEJM200006083422301. PubMed DOI

Olivier M, Hollstein M, Schmeiser HH, Straif K, Wild CP. Upper urinary tract urothelial cancer: where it is A:T. Nat Rev. 2012;12:503–504. doi: 10.1038/nrc3311. PubMed DOI

Olivier M, Weninger A, Ardin M, Huskova H, Castells X, Vallée MP, McKay J, Nedelko T, Muehlbauer KR, Marusawa H, Alexander J, Hazelwood L, Byrnes G, Hollstein M, Zavadil J. Modelling mutational landscapes of human cancers in vitro. Sci Rep. 2014;4:4482. doi: 10.1038/srep04482. PubMed DOI PMC

Orem WH, Feder GL, Finkelman RB. A possible link between Balkan endemic nephropathy and the leaching of toxic organic compounds from Pliocene lignite by groundwater: preliminary investigation. Int J Coal Geol. 1999;40:237–252. doi: 10.1016/S0166-5162(98)00071-8. DOI

Orem WH, Tatu CA, Feder GL, Finkelman RB, Lerch HE, Maharaj SVM, Szilagyi D, Dumitrascu V, Paunescu V, Margineanu F (2002) Environment, geochemistry and the etiology of Balkan endemic nephropathy: lessons from Romania. Facta Univ Ser Archit Civil Eng 9:39–48

Pavlović NM. Balkan endemic nephropathy-current status and future perspectives. Clin Kidney J. 2013;6:257–265. doi: 10.1093/ckj/sft049. PubMed DOI PMC

Pfau W, Schmeiser HH, Wiessler M. Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis. 1990;11:313–319. doi: 10.1093/carcin/11.2.313. PubMed DOI

Pfau W, Schmeiser HH, Wiessler M. 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis. 1990;11:1627–1633. doi: 10.1093/carcin/11.9.1627. PubMed DOI

Pfohl-Leszkowicz A. Ochratoxin A and aristolochic acid involvement in nephropathies and associated urothelial tract tumours. Arh Hig Rada Toksikol. 2009;60:465–483. doi: 10.2478/10004-1254-60-2009-2000. PubMed DOI

Pfohl-Leszkowicz A, Manderville RA. An update on direct genotoxicity as a molecular mechanism of ochratoxin a carcinogenicity. Chem Res Toxicol. 2012;25:252–262. doi: 10.1021/tx200430f. PubMed DOI

Pfohl-Leszkowicz A, Chakor K, Creppy EE, Dirheimer G. DNA adduct formation in mice treated with ochratoxin A. IARC Sci Publ. 1991;115:245–253. PubMed

Pfohl-Leszkowicz A., Grosse Y., Castegnaro M., Nicolov I.G., Chernozemsky I.N., Bartsch H., Betbeder A.M., Creppy E.E., Dirheimer G (1993) Ochratoxin A related DNA adducts. In: Urinary tract tumours of Bulgarian subjects. IARC Science Publications, vol 124, pp 141–148 PubMed

Pfohl-Leszkowicz A, Petkova-Bocharova T, Chernozemsky IN, Castegnaro M. Balkan endemic nephropathy and associated urinary tract tumours: a review on aetiological causes and the potential role of mycotoxins. Food Addit Contam. 2002;19:282–302. doi: 10.1080/02652030110079815. PubMed DOI

Pfohl-Leszkowicz A, Tozlovanu M, Manderville R, Peraica M, Castegnaro M, Stefanovic V. New molecular and field evidences for the implication of mycotoxins but not aristolochic acid in human nephropathy and urinary tract tumor. Mol Nutr Food Res. 2007;51:1131–1146. doi: 10.1002/mnfr.200700045. PubMed DOI

Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, Chong SC, Gan A, Tay ST, Lim WK, Cutcutache I, Huang D, Ler LD, Nairismägi ML, Lee MH, Chang YH, Yu KJ, Chan-On W, Li BK, Yuan YF, Qian CN, Ng KF, Wu CF, Hsu CL, Bunte RM, Stratton MR, Futreal PA, Sung WK, Chuang CK, Ong CK, Rozen SG, Tan P, Teh BT (2013) Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 5:197ra101 PubMed

Radić B, Fuchs R, Peraica M, Lucić A. Ochratoxin A in human sera in the area with endemic nephropathy in Croatia. Toxicol Lett. 1997;91:105–109. doi: 10.1016/S0378-4274(97)03877-0. PubMed DOI

Radonić M, Radosević Z. Clinical features of Balkan endemic nephropathy. Food Chem Toxicol. 1992;30:189–192. doi: 10.1016/0278-6915(92)90032-G. PubMed DOI

Radovanović Z (2002) Epidemiology and etiology of endemic nephro-pathy. In: Radovanović Z, Sinđi M, Polenaković M, Djukanović Lj, Petronić V (eds) Endemic nephropathy. Zavod za žbenike i nastavna sredstva. Belgrade, pp 22–135

Reljic Z, Zlatovic M, Savic-Radojevic A, Pekmezovic T, Djukanovic L, Matic M, Pljesa-Ercegovac M, Mimic-Oka J, Opsenica D, Simic T. Is increased susceptibility to Balkan endemic nephropathy in carriers of common GSTA1 (*A/*B) polymorphism linked with the catalytic role of GSTA1 in ochratoxin a biotransformation? Serbian case control study and in silico analysis. Toxins (Basel) 2014;6:2348–2362. doi: 10.3390/toxins6082348. PubMed DOI PMC

Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29:413–480. doi: 10.3109/03602539709037591. PubMed DOI

Rosenquist TA, Einolf HJ, Dickman KG, Wang L, Smith A, Grollman AP. Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab Disp. 2010;38:761–768. doi: 10.1124/dmd.110.032201. PubMed DOI PMC

Ross D. Quinone reductases multitasking in the metabolic world. Drug Metab Rev. 2004;36:639–654. doi: 10.1081/DMR-200033465. PubMed DOI

Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact. 2000;129:77–97. doi: 10.1016/S0009-2797(00)00199-X. PubMed DOI

Sato N, Takahashi D, Chen SM, Tsuchiya R, Mukoyama T, Yamagata S, Ogawa M, Yoshida M, Kondo S, Satoh N, Ueda S. Acute nephrotoxicity of aristolochic acids in mice. J Pharm Pharmacol. 2004;56:221–229. doi: 10.1211/0022357023051. PubMed DOI

Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzàlez-Porta M, Wozniak MB, Bourgey M, Harnden P, Egevad L, Jackson SM, Karimzadeh M, Arseneault M, Lepage P, How-Kit A, Daunay A, Renault V, Blanché H, Tubacher E, Sehmoun J, Viksna J, Celms E, Opmanis M, Zarins A, Vasudev NS, Seywright M, Abedi-Ardekani B, Carreira C, Selby PJ, Cartledge JJ, Byrnes G, Zavadil J, Su J, Holcatova I, Brisuda A, Zaridze D, Moukeria A, Foretova L, Navratilova M, Mates D, Jinga V, Artemov A, Nedoluzhko A, Mazur A, Rastorguev S, Boulygina E, Heath S, Gut M, Bihoreau MT, Lechner D, Foglio M, Gut IG, Skryabin K, Prokhortchouk E, Cambon-Thomsen A, Rung J, Bourque G, Brennan P, Tost J, Banks RE, Brazma A, Lathrop GM. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun. 2014;5:5135. doi: 10.1038/ncomms6135. PubMed DOI

Schiller A, Gusbeth-Tatomir P, Pavlovic N, Ferluga D, Spasovski G, Covic A. Balkan endemic nephropathy: a still unsolved puzzle. J Nephrol. 2008;21:673–680. PubMed

Schlatter C, Studer-Rohr J, Rásonyi T. Carcinogenicity and kinetic aspects of ochratoxin A. Food Addit Contam. 1996;13(Suppl):43–44. PubMed

Schmeiser HH, Pool BL, Wiessler M. Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver. Carcinogenesis. 1986;7:59–63. doi: 10.1093/carcin/7.1.59. PubMed DOI

Schmeiser HH, Janssen JW, Lyons J, Scherf HR, Pfau W, Buchmann A, Bartram CR, Wiessler M. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residue. Cancer Res. 1990;50:5464–5469. PubMed

Schmeiser HH, Scherf HR, Wiessler M. Activating mutations at codon 61 of the c-Ha-ras gene in thin-tissue sections of tumors induced by aristolochic acid in rats and mice. Cancer Lett. 1991;59:139–143. doi: 10.1016/0304-3835(91)90178-K. PubMed DOI

Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 1996;56:2025–2028. PubMed

Schmeiser HH, Frei E, Wiessler M, Stiborová M. Comparison of DNA adduct formation by aristolochic acids in various in vitro activation systems by 32P-post-labelling: evidence for reductive activation by peroxidases. Carcinogenesis. 1997;18:1055–1062. doi: 10.1093/carcin/18.5.1055. PubMed DOI

Schmeiser HH, Stiborová M, Arlt VM. Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr Opin Drug Discov Devel. 2009;12:141–148. PubMed

Schmeiser HH, Kucab JE, Arlt VM, Phillips DH, Hollstein M, Gluhovschi G, Gluhovschi C, Modilca M, Daminescu L, Petrica L, Velciov S. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania. Environ Mol Mutagen. 2012;53:636–641. doi: 10.1002/em.21732. PubMed DOI

Schmeiser HH, Stiborova M, Arlt VM. 32P-postlabeling analysis of DNA adducts. Methods Mol Biol. 2013;1044:389–401. doi: 10.1007/978-1-62703-529-3_21. PubMed DOI

Schmeiser HH, Nortier JL, Singh R, Gamboa da Costa G, Sennesael J, Cassuto-Viguier E, Ambrosetti D, Rorive S, Pozdzik A, Phillips DH, Stiborova M, Arlt VM. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer. 2014;13:502–507. doi: 10.1002/ijc.28681. PubMed DOI

Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, Grollman AP. Selective toxicity of aristolochic acids I and II. Drug Metab Dispos. 2007;35:1217–1222. doi: 10.1124/dmd.107.014688. PubMed DOI

Shibutani S, Bonala RR, Rosenquist T, Rieger R, Suzuki N, Johnson F, Miller F, Grollman AP. Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int J Cancer. 2010;127:1021–1027. doi: 10.1002/ijc.25141. PubMed DOI PMC

Sidorenko VS, Yeo JE, Bonala RR, Johnson F, Schärer OD, Grollman AP. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res. 2012;40:2494–2505. doi: 10.1093/nar/gkr1095. PubMed DOI PMC

Sidorenko VS, Attaluri S, Zaitseva I, Iden CR, Dickman KG, Johnson F, Grollman AP. Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis. 2014;35:1814–1822. doi: 10.1093/carcin/bgu095. PubMed DOI PMC

Sistkova J, Hudecek J, Hodek P, Frei E, Schmeiser HH, Stiborova M. Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. Neuro Endocrinol Lett. 2008;29:733–737. PubMed

Staneva R, Rukova B, Hadjidekova S, Nesheva D, Antonova O, Dimitrov P, Simeonov V, Stamenov G, Cukuranovic R, Cukuranovic J, Stefanovic V, Polenakovic M, Dimova I, Hlushchuk R, Djonov V, Galabov A, Toncheva D. Whole genome methylation array analysis reveals new aspects in Balkan endemic nephropathy etiology. BMC Nephrol. 2013;14:225. doi: 10.1186/1471-2369-14-225. PubMed DOI PMC

Stefanovic V. Balkan endemic nephropathy: a need for novel aetiological approaches. Q J Med. 1998;91:457–463. doi: 10.1093/qjmed/91.7.457. PubMed DOI

Stefanović V. Diagnostic criteria for endemic (Balkan) nephropathy. In: Strahinjić S, Stefanović V, editors. Current Research in Endemic (Balkan) Nephropathy. Niš: Niš University Press; 1983. pp. 351–363.

Stefanović V, Cosyns JP (2005) Balkan nephropathy. In: Davison AM, Cameron JS, Grunfeld JP, Ponticelli C, Van Ypersele C, Ritz E, Winearls CG (eds). Oxford textbook of clinical nephrology, 3rd ed. Oxford University Press, Oxford, pp 1095–1102

Stefanović V, Radovanovic Z. Balkan endemic nephropathy and associated urothelial cancer. Nat Clin Pract Urol. 2008;5:105–112. doi: 10.1038/ncpuro1019. PubMed DOI

Stefanovic V, Toncheva D, Polenakovic M. Balkan nephropathy. Clin Nephrol. 2015;83(7 suppl 1):64–69. doi: 10.5414/CNP83S064. PubMed DOI

Stefanović V, Toncheva D, Atanasova S, Polenaković M. Etiology of Balkan endemic nephropathy and associated urothelial cancer. Am J Nephrol. 2006;26:1–11. doi: 10.1159/000090705. PubMed DOI

Stefanović V, Jelaković B, Cukuranović R, Bukvić D, Nikolić J, Lukić L, Gluhovschi G, Toncheva D, Polenaković M, Cosyns JP. Diagnostic criteria for Balkan endemic nephropathy: proposal by an international panel. Ren Fail. 2007;29:867–880. doi: 10.1080/08860220701600732. PubMed DOI

Stefanović V, Cukuranovic R, Miljkovic S, Marinkovic D, Toncheva D. Fifty years of Balkan endemic nephropathy: challenges of study using epidemiological method. Ren Fail. 2009;31:409–418. doi: 10.1080/08860220902839097. PubMed DOI

Stiborova M, Mares J, Levova K, Pavlickova J, Barta F, Hodek P, Frei E, Schmeiser HH. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver. Neuro Endocrinol Lett. 2011;32(Suppl 1):121–130. PubMed

Stiborová M, Fernando RC, Schmeiser HH, Frei E, Pfau W, Wiessler M. Characterization of DNA adducts formed by aristolochic acids in the target organ (forestomach) of rats by 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis. 1994;15:1187–1192. doi: 10.1093/carcin/15.6.1187. PubMed DOI

Stiborová M, Frei E, Wiessler M, Schmeiser HH. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem Res Toxicol. 2001;14:1128–1137. doi: 10.1021/tx010059z. PubMed DOI

Stiborová M, Hájek M, Frei E, Schmeiser HH. Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH:cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy. Gen Physiol Biophys. 2001;20:375–392. PubMed

Stiborová M, Hájek M, Vošmiková H, Frei E, Schmeiser HH. Isolation of DT-diaphorase [NAD(P)H dehydrogenase (quinone)] from rat liver cytosol: identification of new substrates, carcinogenic aristolochic acids. Collect Czech Chem Commun. 2001;66:959–972. doi: 10.1135/cccc20010959. DOI

Stiborová M, Frei E, Sopko B, Wiessler M, Schmeiser HH. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis. 2002;23:617–625. doi: 10.1093/carcin/23.4.617. PubMed DOI

Stiborová M, Martínek V, Rýdlová H, Hodek P, Frei E. Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res. 2002;62:5678–5684. PubMed

Stiborová M, Frei E, Sopko B, Sopková K, Marková V, Lanková M, Kumstýrová T, Wiessler M, Schmeiser HH. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis. 2003;24:1695–1703. doi: 10.1093/carcin/bgg119. PubMed DOI

Stiborová M, Frei E, Hodek P, Wiessler M, Schmeiser HH. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer. 2005;113:189–197. doi: 10.1002/ijc.20564. PubMed DOI

Stiborová M, Sopko B, Hodek P, Frei E, Schmeiser HH, Hudeček J. The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. Cancer Lett. 2005;229:193–204. doi: 10.1016/j.canlet.2005.06.038. PubMed DOI

Stiborová M, Frei E, Arlt VM, Schmeiser HH. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res. 2008;658:55–67. doi: 10.1016/j.mrrev.2007.07.003. PubMed DOI

Stiborová M, Frei E, Schmeiser HH. Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. Kidney Int. 2008;73:1209–1211. doi: 10.1038/ki.2008.125. PubMed DOI

Stiborová M, Frei E, Arlt VM, Schmeiser HH. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009;153:5–11. doi: 10.5507/bp.2009.001. PubMed DOI

Stiborová M, Mareš J, Frei E, Arlt VM, Martínek V, Schmeiser HH. The human carcinogen aristolochic acid I is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ Mol Mutagen. 2011;52:448–459. doi: 10.1002/em.20642. PubMed DOI

Stiborová M, Levová K, Bárta F, Shi Z, Frei E, Schmeiser HH, Nebert DW, Phillips DH, Arlt VM. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol Sci. 2012;125:345–358. doi: 10.1093/toxsci/kfr306. PubMed DOI PMC

Stiborová M, Dračínská H, Martínek V, Svášková D, Hodek P, Milichovský J, Hejduková Ž, Brotánek J, Schmeiser HH, Frei E. Induced expression of cytochrome P450 1A and NAD(P)H:quinone oxidoreductase determined at mRNA, protein, and enzyme activity levels in rats exposed to the carcinogenic azo dye 1-phenylazo-2-naphthol (Sudan I) Chem Res Toxicol. 2013;26:290–299. doi: 10.1021/tx3004533. PubMed DOI

Stiborová M, Martínek V, Frei E, Arlt VM, Schmeiser HH. Enzymes metabolizing aristolochic acid and their contribution to the development of Aristolochic acid nephropathy and urothelial cancer. Curr Drug Metab. 2013;14:695–705. doi: 10.2174/1389200211314060006. PubMed DOI

Stiborová M, Frei E, Arlt VM, Schmeiser HH. Knock-out and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid. Xenobiotica. 2014;44:135–145. doi: 10.3109/00498254.2013.848310. PubMed DOI

Stiborová M, Frei E, Schmeiser HH, Arlt VM, Martínek V. Mechanisms of enzyme-catalyzed reduction of two carcinogenic nitro-aromatics, 3-nitrobenzanthrone and aristolochic acid I: experimental and theoretical approaches. Int J Mol Sci. 2014;15:10271–10295. doi: 10.3390/ijms150610271. PubMed DOI PMC

Stiborová M, Levová K, Bárta F, Sulc M, Frei E, Arlt VM, Schmeiser HH. The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats. Mutagenesis. 2014;29:189–200. doi: 10.1093/mutage/geu004. PubMed DOI

Stiborová M, Bárta F, Levová K, Hodek P, Frei E, Arlt VM, Schmeiser HH. The influence of ochratoxin A on DNA adduct formation by the carcinogen aristolochic acid in rats. Arch Toxicol. 2015;89:2141–2158. doi: 10.1007/s00204-014-1360-1. PubMed DOI

Stiborová M, Barta F, Levova K, Hodek P, Schmeiser HH, Arlt VM, Martínek V. A mechanism of O-demethylation of aristolochic acid I by cytochromes P450 and their contributions to this reaction in human and rat livers: experimental and theoretical approaches. Int J Mol Sci. 2015;16:27561–27575. doi: 10.3390/ijms161126047. PubMed DOI PMC

Tanchev Y, Evstatiev ZV, Dorosiev G, Pencheva ZH, Zvetkov G. Prouchavaniia na nefrititev v vrachanska okolia. [Study on nephritis in the region of Vratza, in Bulgarian] Savr Med. 1956;7:14–29. PubMed

Tatu CA, Orem WH, Finkelman RB, Feder GL. The etiology of Balkan endemic nephropathy: still more questions than answers. Environ Health Perspect. 1998;106:689–700. doi: 10.1289/ehp.98106689. PubMed DOI PMC

Toncheva D. Genetic studies in BEN and associated urothelial cancers. Coll Antropol. 2006;30(suppl 1):34.

Toncheva D, Dimitrov T. Genetic predisposition to Balkan endemic nephropathy. Nephron. 1996;72:564–569. doi: 10.1159/000188940. PubMed DOI

Toncheva D, Dimitrov T, Tzoneva M. Cytogenetic studies in Balkan endemic nephropathy. Nephron. 1988;48:18–21. doi: 10.1159/000184862. PubMed DOI

Toncheva DI, Gergov TD, Tzoneva MT, Bouchakliev ZP. Spontaneous and induced chromosome aberrations in Balkan endemic nephropathy. Kidney Int Suppl. 1991;34:S97–S101. PubMed

Toncheva D, Dimitrov T, Stojanova S. Etiology of Balkan endemic nephropathy: a multifactorial disease? Eur J Epidemiol. 1998;14:389–394. doi: 10.1023/A:1007445120729. PubMed DOI

Toncheva DI, von Ahsen N, Atanasova SY, Dimitrov TG, Armstrong VM, Oellerich M. Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. J Nephrol. 2004;17:384–389. PubMed

Toncheva D, Mihailova-Hristova M, Vazharova R, Staneva R, Karachanak S, Dimitrov P, Simeonov V, Ivanov S, Balabanski L, Serbezov D, Malinov M, Stefanovic V, Čukuranović R, Polenakovic M, Jankovic-Velickovic L, Djordjevic V, Jevtovic-Stoimenov T, Plaseska-Karanfilska D, Galabov A, Djonov V, Dimova I. NGS nominated CELA1, HSPG2, and KCNK5 as candidate genes for predisposition to Balkan endemic nephropathy. Biomed Res Int. 2014;2014:920723. doi: 10.1155/2014/920723. PubMed DOI PMC

Tsoneva M, Ts Dimitrov, Toncheva D. Familial cytogenetic studies in Balkan endemic nephropathy. II. Vutr Boles. 1985;24:61–66. PubMed

Turesky RJ. Perspective: ochratoxin A is not a genotoxic carcinogen. Chem Res Toxicol. 2005;18:1082–1090. doi: 10.1021/tx050076e. PubMed DOI

Turesky RJ, Yun BH, Brennan P, Mates D, Jinga V, Harnden P, Banks RE, Blanche H, Bihoreau MT, Chopard P, Letourneau L, Lathrop GM, Scelo G. Aristolochic acid exposure in Romania and implications for renal cell carcinoma. Br J Cancer. 2016;114:76–80. doi: 10.1038/bjc.2015.402. PubMed DOI PMC

Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, Vanhaelen M. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993;341:387–391. doi: 10.1016/0140-6736(93)92984-2. PubMed DOI

Voice TC, McElmurry SP, Long DT, Dimitrov P, Ganev VS, Peptropoulos EA. Evaluation of the hypothesis that Balkan endemic nephropathy is caused by drinking water exposure to contaminants leaching from Pliocene coal deposits. J Exp Sci Environ Epidemiol. 2006;16:515–524. doi: 10.1038/sj.jes.7500489. PubMed DOI

Wang B, Wang J, Huang SQ, Su HH, Zhou SF. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab. 2009;10:781–834. doi: 10.2174/138920009789895480. PubMed DOI

Wang Y, Meng F, Arlt VM, Mei N, Chen T, Parsons BL. Aristolochic acid-induced carcinogenesis examined by ACB-PCR quantification of H-Ras and K-Ras mutant fraction. Mutagenesis. 2011;26:619–628. doi: 10.1093/mutage/ger023. PubMed DOI

Wang Y, Arlt VM, Roufosse CA, McKim KL, Myers MB, Phillips DH, Parsons BL. ACB-PCR measurement of H-ras codon 61 CAA → CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues. Environ Mol Mutagen. 2012;53:495–504. doi: 10.1002/em.21710. PubMed DOI

Wernerson A, Wijkström J, Elinder CG. Update on endemic nephropathies. Curr Opin Nephrol Hypertens. 2014;23:232–238. doi: 10.1097/01.mnh.0000444911.32794.e7. PubMed DOI

Xiao Y, Ge M, Xue X, Wang H, Wu X, Li L, Liu L, Qi X, Zhang Y, Li Y, Xie T, Gu J, Ren J. Detoxication role of hepatic cytochrome P450s in the kidney toxicity induced by aristolochic acid. Kidney Int. 2008;73:1231–1239. doi: 10.1038/ki.2008.103. PubMed DOI

Xue X, Xiao Y, Zhu H, Wang H, Liu Y, Xie T, Ren J. Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury. Nephrol Dial Transplant. 2008;23:3074–3081. doi: 10.1093/ndt/gfn262. PubMed DOI

Yu FY, Wu TS, Chen TW, Liu BH. Aristolochic acid I induced oxidative DNA damage associated with glutathione depletion and ERK1/2 activation in human cells. Toxicol In Vitro. 2011;25:810–816. doi: 10.1016/j.tiv.2011.01.016. PubMed DOI

Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, Bonala R, Johnson F, Dickman KG, Grollman AP, Turesky RJ. Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. Chem Res Toxicol. 2012;25:1119–1131. doi: 10.1021/tx3000889. PubMed DOI PMC

Yun BH, Rosenquist TA, Nikolić J, Dragičević D, Tomić K, Jelaković B, Dickman KG, Grollman AP, Turesky RJ. Human formalin-fixed paraffin-embedded tissues: an untapped specimen for biomonitoring of carcinogen DNA adducts by mass spectrometry. Anal Chem. 2013;85:4251–4258. doi: 10.1021/ac400612x. PubMed DOI PMC

Yun BH, Sidorenko VS, Rosenquist TA, Dickman KG, Grollman AP, Turesky RJ. New approaches for biomonitoring exposure to the human carcinogen aristolochic acid. Toxicol Res (Camb) 2015;4:763–776. doi: 10.1039/C5TX00052A. PubMed DOI PMC

Zhu S, Wang Y, Jin J, Guan C, Li M, Xi C, Ouyang Z, Chen M, Qiu Y, Huang M, Huang Z. Endoplasmic reticulum stress mediates aristolochic acid I-induced apoptosis in human renal proximal tubular epithelial cells. Toxicol In Vitro. 2012;26:663–671. doi: 10.1016/j.tiv.2012.03.005. PubMed DOI

Aristolochic acid-associated cancers: a public health risk in need of global action

Co-Exposure to Aristolochic Acids I and II Increases DNA Adduct Formation Responsible for Aristolochic Acid I-Mediated Carcinogenicity in Rats

The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro

Analyses of biomarkers of exposure to nephrotoxic mycotoxins in a cohort of patients with renal tumours

DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer

Comparison of the oxidation of carcinogenic aristolochic acid I and II by microsomal cytochromes P450 in vitro: experimental and theoretical approaches